InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 ...

Northwestern Medicine investigators have uncovered a missing link behind the harmful effects of autoantibodies linked to ...

Expands AI-Driven Infrastructure Powering Evidence-Based Patient Activation Across Enterprise Healthcare SAN DIEGO and BIRMINGHAM, Ala., March 25, 2026 /PRNewswire/ -- Guideway Care today announced ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...

Additions Bring Extensive Capital Markets and Business Transaction Expertise to Company as it Advances Pegtarazimod into Late-Stage Clinical TrialsNORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences ...

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...

Nespresso is deepening its partnership with Californian specialty coffee pioneer Blue Bottle Coffee, bringing the Nespresso ...

A new deep-brain BCI from Tsinghua University uses the lateral ventricles to record neural signals. This "lantern" electrode ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

Short-term air pollution alerts can significantly improve air quality and prevent tens of thousands of premature deaths, ...

EU social policy measures outputs efficiently — but the lived experience of its supposed beneficiaries tells a very different ...